These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11365712)

  • 21. A new HAART on the horizon says the proof is in the potency.
    AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New expanded access drugs for use in combination therapy.
    Newsline People AIDS Coalit N Y; 1998 Dec; ():22-3. PubMed ID: 11367085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amprenavir study results released.
    AIDS Patient Care STDS; 1999 Dec; 13(12):754. PubMed ID: 10743545
    [No Abstract]   [Full Text] [Related]  

  • 25. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.
    Wasmuth JC; Herhaus C; Römer K; Salzberger B; Kaiser R; Schliefer K; Voigt E; Rockstroh JK
    AIDS; 2002 May; 16(7):1077-8. PubMed ID: 11953478
    [No Abstract]   [Full Text] [Related]  

  • 27. New drugs: amprenavir and abacavir.
    TreatmentUpdate; 1998 Apr; 10(2):3-4. PubMed ID: 11365435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antivirals update.
    Proj Inf Perspect; 1998 Dec; (26):8-10. PubMed ID: 11366501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New expanded access drugs for use in combination therapy.
    Notes Undergr; 1998; (No 37):suppl 1-2. PubMed ID: 11365823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
    Falloon J; Ait-Khaled M; Thomas DA; Brosgart CL; Eron JJ; Feinberg J; Flanigan TP; Hammer SM; Kraus PW; Murphy R; Torres R; Masur H;
    AIDS; 2002 Feb; 16(3):387-96. PubMed ID: 11834950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of the naive patient.
    Bartlett JG
    Hopkins HIV Rep; 1999 Mar; 11(2):1, 10-1. PubMed ID: 11366244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
    Castillo SA; Hernandez JE; Brothers CH
    Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Options when HIV treatments fail.
    Treat Rev; 1998; (No 28):7-9. PubMed ID: 11365426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lustgarten S; Squires KE; Meyer WA; Acosta EP; Schackman BR; Pilcher CD; Murphy RL; Maher WE; Witt MD; Reichman RC; Snyder S; Klingman KL; Kuritzkes DR;
    N Engl J Med; 2004 Apr; 350(18):1850-61. PubMed ID: 15115831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine.
    De Wit S; Cassano P; Hermans P; Kabeya K; Gerard M; O'Doherty E; Clumeck N
    AIDS; 1999 May; 13(7):864-5. PubMed ID: 10357390
    [No Abstract]   [Full Text] [Related]  

  • 37. New study shows efavirenz effective with d4T and 3TC.
    AIDS Alert; 1999 May; 14(5):60. PubMed ID: 11366404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple-nucleoside regimens versus efavirenz.
    De Luca A; Di Giambenedetto S
    N Engl J Med; 2004 Aug; 351(7):717-9; author reply 717-9. PubMed ID: 15306677
    [No Abstract]   [Full Text] [Related]  

  • 39. Expanded access.
    Notes Undergr; 1997 Nov; (No 36):6. PubMed ID: 11365207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moving forward: a treatment overview from the 12th World AIDS Conference.
    Agosto M
    Newsline People AIDS Coalit N Y; 1998 Sep; ():6-11. PubMed ID: 11367497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.